Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Digital Transformation

Set Alert for Digital Transformation

Amgen Joins AI/ML Gold Rush With Generate Deal

Deal Snapshot: At a same-day conference, Amgen’s CEO outlined the importance of AI/ML to the company’s drug development strategy, as numerous large biopharma companies have recently made similar deals.

Artificial Intelligence Deals

How Novartis Is Tailoring Its Strategy In Asia Pacific, Middle East and Africa

Iris Zemzoum, Novartis Pharma's president for Asia Pacific, Middle East and Africa, outlines how the company is shaping its strategy in the region, which comes with “extremes” in market profiles, via a distinct archetype that factors in commonalities between national healthcare systems. The company is also progressing interesting initiatives in digital therapeutics.

Commercial Coronavirus COVID-19

Roche And Recursion’s AI Drug Discovery Pact To Focus On Neuroscience

The 10-year deal aims to use artificial intelligence to map out the cellular biology behind neuroscience and oncology and accelerate drug discovery in another boost to the field.

Artificial Intelligence Companies

BenevolentAI Goes Public In Europe’s Largest SPAC

The UK computational medicines specialist is listing on the Euronext Amsterdam after linking up with healthcare-focused special purpose acquisition corporation Odyssey which is advised by former Sanofi CEO Olivier Brandicourt.

M & A Artificial Intelligence

GSK Dives Into Neurology With £30m Oxford University Pact

After returning to the neuroscience space in the summer through a big-money deal with Alector, GlaxoSmithKline is setting up an institute with the University of Oxford that will target neurological diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, frontal temporal dementia, ALS and pain.

Deals Neurology

Scorching COVID-19 Era Returns From India Biotech, Healthcare Funds Outpace The Globe

Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.

Commercial Financing

The Inexorable Rise Of Exscientia

The UK firm has not completed a clinical trial yet but having raised over $350m from its NASDAQ initial public offering and an extra $160m from a private placement, Exscientia's future looks extremely bright.

Financing Artificial Intelligence

Digital Events, Social Media Move Up Pharma’s Marketing Playbook

Pharma is switching up its digital marketing playbook to map multiple touch points, including digital congresses and social media chats to deliver not just a product but a better customer experience, executives from Pfizer, Novo Nordisk and ViiV Healthcare say.

Commercial Digital Health

Janssen’s Sarich: Randomized Controlled Trials, Real-World Evidence Go Best Together

Janssen’s Troy Sarich outlines why it’s hard to emulate randomized controlled trials with real-world evidence studies, emphasizing that the two are “not in competition.” He also highlights the huge strides made by AI-driven technology firms to provide “research-ready” structured data and new game-changing advances in the area of health sensors.

Research & Development Clinical Trials

Moderna CCO Highlights Panomics, Pre-emptive Care As Pharma’s Future

Moderna’s CCO Corinne Le Goff highlighted panomics and pre-emptive care as the industry’s future at a recent event, even as she saw on-shoring and “regaining sovereignty” over health expenditure as being essential to medicines security.

Commercial Digital Health

Digital Acceleration And ‘Broken’ Customer Experience: What Pharma Should Look Out For

Biopharma experts discuss at a summit core issues around ensuring that fast-paced digital acceleration does not jeopardize the overall experience of healthcare professionals. Clarity about customer needs/behaviors, embracing a fail-fast, learn-fast mindset and measuring customer experience were among the aspects touched upon.

Commercial Digital Health

Ex-Amgen CIO McKenzie: 'We All Have To Think Like Software Companies'

Amgen’s former chief information officer Diana McKenzie highlights the inroads made by technology firms in healthcare and how life science companies can adapt from them while leveraging core capabilities at scale.

Commercial Digital Health
See All
UsernamePublicRestriction

Register